The key catalyst is the XTX501 Phase 1 data expected in Q4 2027, which is over a year away. Near-term focus is on IND filings for XTX602 and XTX701 in Q4 2027 and the Gilead option data package in H1 2027. Cash runway into Q1 2028 provides no immediate financing pressure.
Drugs in focus
XLO drug pipeline →XTX501
● Neutral Named in this press release- Impact
- Phase
- Phase 1/2
- Time to market
- XTX501 is in early clinical development (Phase 1/2). Initial Phase 1 data is expected in Q4 2027. If successful, a registrational trial would follow, meaning potential approval is likely several years away (late 2029 or later under an accelerated timeline).
- Next catalyst
- None dated
What to watchThe next meaningful catalyst for XTX501 is the initial Phase 1 data readout in Q4 2027, more than a year away. In the near term, watch for a trial-in-progress poster at the SITC meeting in November 2026 and any early safety signals. Xilio's cash runway into Q1 2028 provides a long enough runway to reach that data, but the stock may trade on broader pipeline news and quarterly earnings in the interim. The competitive landscape, particularly Innovent/Takeda's more advanced IBI363 program, will be an important benchmark for XTX501's potential.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $8.53entry
- T+1 · 6d ago −0.70%α −2.02% · $8.47
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Xilio reported Q3 2026 collaboration revenue of $10.0M (down from $19.1M a year ago) and net loss of $5.9M (improved from $16.3M loss in Q3 2025). The company dosed the first patient in its Phase 1/2 trial for XTX501 and expects to report initial data in Q4 2027. Cash of $122.2M is expected to fund operations into Q1 2028.
Key Financial Metrics
Key Facts
- Collaboration and license revenue was $10.0M for Q3 2026, down from $19.1M in Q3 2025.
- Net loss was $5.9M for Q3 2026, compared to $16.3M net loss in Q3 2025.
- Cash and cash equivalents were $122.2M as of September 30, 2026, down from $137.5M at year-end 2025.
- First patient dosed in Phase 1/2 trial for XTX501 (PD-1/masked IL-2 bispecific) in metastatic NSCLC.
- Initial Phase 1 data for XTX501 expected in Q4 2027.
- IND filings for XTX602 and XTX701 planned for Q4 2027.
- Appointed Yariv Houvras, M.D., Ph.D. as chief medical officer in September 2026.
- Cash runway expected into Q1 2028, excluding potential warrant exercise proceeds of up to $36.2M.
Financial Impact
Revenue decline of $9.1M YoY; net loss improved by $10.4M YoY; cash burn of $15.3M in Q3 2026.
Risk Factors
- Revenue is entirely collaboration-based and declined significantly YoY.
- No approved products or near-term revenue catalysts; all programs are preclinical or early clinical.
- Potential dilution from Series C warrant exercises (up to $36.2M) in Q4 2026.
- Clinical-stage biotech with no path to profitability in the near term.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3399365 |
Track record
16 reports on XLO
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +19.92% at T+60 after the May 12, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $7.70 Now $7.70 −0.00% settles Nov 24
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $7.96 Now $7.70 −3.27% settles Nov 23
- Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $8.24 Now $7.70 −6.55% settles Nov 19
- Nov 10, 20266d ago Press Release Neutral 4/10 Viewing Entry $8.53 Now $7.70 −9.73% settles Nov 17
- Oct 26, 202621d ago Press Release Neutral 4/10 Entry $7.31 to $8.03 Now $7.70 +5.34% ▲ +9.85% +11.11% vs SPY
- Aug 12, 202613w ago 8-K Bullish 7/10 No price data
- Aug 12, 202613w ago Press Release Bullish 7/10 Entry $9.05 to $9.41 Now $7.70 −14.92% ▲ +3.98% +4.42% vs SPY
- Jun 1, 202624w ago EFFECT Bearish 5/10 Entry $8.25 to $7.70 Now $7.70 +6.67% ▲ +6.67% +3.92% vs SPY
- May 27, 202624w ago S-3/A Neutral 4/10 Entry $8.52 to $8.15 Now $7.70 −9.62% ▼ −4.40% −4.35% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers